FOLH1 and posterior cortical atrophy: (191), FDA-approved poly-lactic-glycolic changeable liquid PFP, photosensitizer IR780, and therapeutic drugs Paclitaxel, to perform PTT combined chemotherapy on PSMA+ C4-2 PCa tissues.